274 related articles for article (PubMed ID: 10657016)
1. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
[TBL] [Abstract][Full Text] [Related]
2. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
[TBL] [Abstract][Full Text] [Related]
3. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
4. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.
Kerkhof M; van Dekken H; Steyerberg EW; Meijer GA; Mulder AH; de Bruïne A; Driessen A; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD;
Histopathology; 2007 Jun; 50(7):920-7. PubMed ID: 17543082
[TBL] [Abstract][Full Text] [Related]
5. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
7. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
8. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies.
Baak JP; ten Kate FJ; Offerhaus GJ; van Lanschot JJ; Meijer GA
J Clin Pathol; 2002 Dec; 55(12):910-6. PubMed ID: 12461055
[TBL] [Abstract][Full Text] [Related]
9. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
10. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
11. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.
Kaye PV; Haider SA; Ilyas M; James PD; Soomro I; Faisal W; Catton J; Parsons SL; Ragunath K
Histopathology; 2009 May; 54(6):699-712. PubMed ID: 19438745
[TBL] [Abstract][Full Text] [Related]
12. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
13. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
14. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
15. [Barrett's oesophagus: endoscopic diagnosis and follow-up].
Ponsot P
Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849
[TBL] [Abstract][Full Text] [Related]
16. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.
Lörinc E; Jakobsson B; Landberg G; Veress B
Histopathology; 2005 Jun; 46(6):642-8. PubMed ID: 15910595
[TBL] [Abstract][Full Text] [Related]
17. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies.
Downs-Kelly E; Mendelin JE; Bennett AE; Castilla E; Henricks WH; Schoenfield L; Skacel M; Yerian L; Rice TW; Rybicki LA; Bronner MP; Goldblum JR
Am J Gastroenterol; 2008 Sep; 103(9):2333-40; quiz 2341. PubMed ID: 18671819
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
20. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
